Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance

William Blair analyst Sami Corwin has maintained their bullish stance on ZVRA stock, giving a Buy rating today.

Sami Corwin has given his Buy rating due to a combination of factors that highlight Zevra Therapeutics’ promising outlook. The company’s expertise in rare diseases and the impressive launch of Miplyffa, which has shown strong patient enrollment and conversion from the U.S. Expanded Access Program (EAP) to commercial patients, are key drivers of this positive assessment. The high demand for Miplyffa, especially in the European market, where there is a significant number of EAP patients, further supports the potential for a successful commercial launch in 2025.
Additionally, Zevra’s financial performance has been robust, with revenue exceeding expectations for the second consecutive quarter. The revenue from Miplyffa alone surpassed estimates, indicating strong market acceptance. Furthermore, Zevra’s management has effectively streamlined operations, resulting in lower-than-expected operating expenses. These factors, combined with the anticipation of a transformational year ahead, contribute to the Buy rating for Zevra Therapeutics.

In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $19.00 price target.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZVRA in relation to earlier this year.